General Information of Drug (ID: DMYALON)

Drug Name
(2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine Drug Info
Synonyms (S)-2-(6-methoxyindazol-1-yl)-1-methylethylamine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11708275
TTD Drug ID
DMYALON

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting 5-HT 2B receptor (HTR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [3]
Triflupromazine DMKFQJP Nausea MD90 Approved [4]
Minaprine DM0EP7M Depression 6A70-6A7Z Approved [5]
SPN-812 DMTV7XH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [6]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [7]
PRX-08066 DMR7H2V Pulmonary arterial hypertension BB01.0 Phase 2 [8]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [9]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [9]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [9]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [3]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [10]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [11]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [12]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [13]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [14]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [15]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [16]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [17]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 2C receptor (HTR2C)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [3]
Lorcaserin DMG6OYJ Obesity 5B81 Approved [19]
Tramadol DMRQD04 Osteoarthritis FA00-FA05 Approved [20]
Mirtazapine DML53ZJ Depression 6A70-6A7Z Approved [21]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [22]
Methysergide DM1EF73 Migraine 8A80 Approved [23]
Eltoprazine DMW6C81 Attention deficit hyperactivity disorder 6A05.Z Phase 3 [24]
M100907 DM7ZFBA Sleep-wake disorder 7A00-7B2Z Phase 3 [25]
SR46349B DM1ODMR Primary insomnia 7A00 Phase 3 [26]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [2]
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Inhibitor [2]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Inhibitor [1]

References

1 Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82.
2 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28.
3 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
4 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
5 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
6 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
7 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
8 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
9 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
10 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
11 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
12 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
13 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
14 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
15 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
16 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
17 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
18 Clinical pipeline report, company report or official report of Lundbeck.
19 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
20 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
21 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
22 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
23 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
24 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
25 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
26 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.